India, Aug. 31 -- Trinity Biotech plc (TRIB), a commercial-stage biotechnology company, on Monday provided several updates regarding its diagnostics business, pipeline, and current standing with respect to Nasdaq Listing Rules.
The Irish company is focused on developing, manufacturing, and marketing various diagnostic tools, including wearable biosensors and solutions for diabetes management.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Business Updates:
Trinity completed the commercial rollout of the HbA1c column system for its Premier Hb210 analyzer, that previously received clearance from the U.S. Food and Drug Administration (FDA). The high-capacity column system was indicated to provide up to...